Safety and antitumor activity of the first-in-class EGFR–HER3 bispecific antibody–drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase Ib study☆
Publication date: November 2026 Source: Annals of Oncology, Volume 37, Issue 11 Author(s): J. Zhang, Y. Meng, Y. Du, T. Sun, J. Cui, Y. Chen, Y. Sun, Y. Wang, W. Chen, F. Xu, Y. Shi, Y. Chen, K. Wang, G. Jin, H. Zhou, Z. Zhuang, W. Xie, Z. Wang, M. Sun, Q. Wen
Safety and antitumor activity of the first-in-class EGFR–HER3 bispecific antibody–drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase Ib study☆. // Annals of Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S0923753426066342?dgcid=rss_sd_all
Safety and antitumor activity of the first-in-class EGFR–HER3 bispecific antibody–drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase Ib study☆. Annals of Oncology. https://www.sciencedirect.com/science/article/pii/S0923753426066342?dgcid=rss_sd_all
“Safety and antitumor activity of the first-in-class EGFR–HER3 bispecific antibody–drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase Ib study☆.” Annals of Oncology.
@article{article35965,
title = {Safety and antitumor activity of the first-in-class EGFR–HER3 bispecific antibody–drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase Ib study☆},
journal = {Annals of Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S0923753426066342?dgcid=rss_sd_all}
}